Is ARVN Worth Buying in 2026?

Arvinas, Inc

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-05-03

Here’s whether Arvinas, Inc (ARVN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.

🔵
Neutral

Positives: trading above the 200-day MA (long-term uptrend intact); RSI 49 — healthy momentum range; strong 1-year return of +45.4%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-3.64% over 10 days); 3-month momentum negative (-24.0%). Currently 27.6% off its 52-week high. Score: +1/7.

Ready to act on this? 📈 Trade on Webull

ARVN is holding above its long-term 200-day MA ($10.45) but has slipped below the 50-day MA ($11.53), pointing to short-term weakness in an otherwise intact trend. An RSI of 48.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +45.4% compares to +27.9% for SPY (beat the market by 17.5%). The current 27.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $14,537 today
vs. S&P 500 (SPY) — same period beat market by 17.5%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($10.45)
Above 50-day MA ($11.53)
RSI(14) neutral zone (30–70) — currently 48.5
Positive return (+45.4%)
!Within 10% of period high (−27.6%)
Period Range $10.51
$5.90 $14.51
RSI (14) 48.5
0 · OversoldOverbought · 100

Key Metrics

Price$10.51
Period Return+45.4%
Period High$14.51
Period Low$5.90
Drawdown−27.6%
MA-50$11.53
MA-200$10.45
RSI (14)48.5
Avg Volume (30d)851K
vs. SPYbeat by 16.3%
Return Rank#409 of 1236

Trade ARVN

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers